In an effort to further individualize therapy and avoid over-treating patients, researchers report a new study using PET scans has identified a biomarker that may accurately predict which patients with one type of HER2-positive breast cancer might best benefit from standalone HER2-targeted agents, without the need for standard chemotherapy.
from Women's Health News -- ScienceDaily https://ift.tt/2tzm61D
0 comments:
Post a Comment